VetStem Biopharma, a leader in Veterinary Regenerative Medicine and PALL Life Sciences, leader in filtration, separation and purification, announced a clinical research and technology distribution agreement for Pall’s unique filtration based Veterinary Platelet Enhancement Therapy system (V-PET).
“VetStem was a logical choice, given that they are the stem cell leader in the US and Canadian markets. We share a commitment to ongoing research in the life science fields,” stated Mr. Antoine, Pall Sales Manager, Americas Cell Therapy.
“The V-PET platelet enhancement therapy system complements perfectly our current portfolio of regenerative medicine solutions,” said Dr Nahama, president and chief commercial officer for VetStem. “It is validated for use in dogs and horses. Because the technology is gravity filtration based, it does not require a centrifuge to process samples. Any veterinarian in the field, at the patients’ home or in a hospital setting can have enhanced platelet therapy ready for injection in about 30 minutes.”
“Stem Cell Therapy and enhanced platelet therapy are highly complementary depending on the disease state and the specific client needs,” added Dr Nahama.
Platelet therapy promotes healing when the body requires help to kick start its natural internal repair processes. Platelets contain a variety of growth factors that, once released, attract progenitor cells, enhance wound healing and stimulate tissue regeneration. Since the animal is the donor and recipient of the therapy, the safety profile (autologous therapy) is very favorable.
The most common uses of platelet therapy are for indications such as hard to heal wounds, tendon and ligament injuries, as well as joint disease (osteoarthritis).
V-PET will be available to US and Canada veterinarians directly through VetStem Biopharma, or selected distributors, starting late November 2015.
VetStem Biopharma is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.” In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industrial manufacturing. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information, please visit: www.pall.com, or follow us on social media at: Facebook; Google+; LinkedIn ; Twitter; and YouTube.
